Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia
- 8 December 2008
- journal article
- review article
- Published by Elsevier BV in Trends in Pharmacological Sciences
- Vol. 30 (1), 25-31
- https://doi.org/10.1016/j.tips.2008.10.006
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disordersNature Reviews Drug Discovery, 2009
- Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophreniaTrends in Neurosciences, 2008
- Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulatedNeuropharmacology, 2008
- Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trialNature Medicine, 2007
- Dysfunctional and Compensatory Prefrontal Cortical Systems, Genes and the Pathogenesis of SchizophreniaCerebral Cortex, 2007
- Positive Allosteric Modulation of Metabotropic Glutamate 5 (mGlu5) Receptors Reverses N-Methyl-D-Aspartate Antagonist-Induced Alteration of Neuronal Firing in Prefrontal CortexBiological Psychiatry, 2007
- NMDA-induced potentiation of mGluR5 is mediated by activation of protein phosphatase 2B/calcineurinNeuropharmacology, 2005
- Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): Efficacy in an animal model for schizophreniaBioorganic & Medicinal Chemistry Letters, 2005
- A novel, competitive mGlu5 receptor antagonist (LY344545) blocks DHPG‐induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slicesBritish Journal of Pharmacology, 2000
- Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implicationsLife Sciences, 1997